1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Scleroderma, Localized: new trials by email Literature Review of Scleroderma, Localized trials Research Report on Scleroderma, Localized
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) FCX-013, veledimex - Morphea, Scleroderma, Localized | Phase 1 / Phase 2 | Terminated | Castle Creek Biosciences, LLC. | 1 | 2019-12-18 | 2024-01-23 |
| Study to Assess Sarilumab in Halting Progression of Morphea Sarilumab - Morphea, Plaque Form | Phase 1 / Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-01 | 2021-09-08 | |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
Scleroderma, Diffuse (2) · Acne Keloid (1) · Cicatrix (1) · Granuloma Annulare (1) · Keloid (1)
Connective Tissue Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Scleroderma, Systemic (2) · Acneiform Eruptions (1) · Collagen Diseases (1) · Fibrosis (1) · Folliculitis (1) · Granuloma (1) · Hair Diseases (1) · Necrobiotic Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Drug Delivery Systems (1) · sarilumab (1) · veledimex (1)
Castle Creek Biosciences, LLC. (1) · Massachusetts General Hospital (1) · University of Michigan (1)
United States (3)